Regeneron partners with US Government to develop Covid-19 antibody vaccine

23 Aug 2023
www.pharmaceutical-technology.com
VaccineLicense out/in
Regeneron partners with US Government to develop Covid-19 antibody vaccine
Preview
Source: Pharmaceutical Technology
Phalguni Deswal
@Phalguni_GD
Regeneron partners with US Government to develop Covid-19 antibody vaccine
Preview
Source: Pharmaceutical Technology
As per the current agreement, Regeneron will independently invent an antibody candidate for Covid-19. Image Credit: myboys.me / Shutterstock.
US-based Biomedical Advanced Research and Development Authority (BARDA) has partnered with Regeneron on the Covid-19 monoclonal antibody vaccine clinical development programme.
A part of the US Government’s Strategic Preparedness and Response division, BARDA has entered the partnership as part of Project NextGen. The project plans to leverage public-private partnerships to develop vaccines and therapies for Covid-19 SARS-CoV-2 and other future strains.
Recommended Reports
Regeneron partners with US Government to develop Covid-19 antibody vaccine
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Recombinant Rotavirus (Trivalent) Vaccine in Rotavirus Infections GlobalData
Regeneron partners with US Government to develop Covid-19 antibody vaccine
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - DTwP-Hep B-IPV-Hib Vaccine in Poliomyelitis GlobalData
View allCompanies IntelligenceRegeneron GmbHBiomedical Advanced Research and Development AuthorityView all
There has been an increased demand for Covid-19 vaccines that target the new variants, specifically Omicron, after the European Medicines Agency’s (EMA) decision to seek SARS-CoV-2 XBB 1.5 Omicron subvariant Covid-19 vaccines.
As per the current agreement, Regeneron will independently invent an antibody candidate for Covid-19. Following this, both parties will evaluate the further development of the candidate. BARDA will then fund up to $326m for the vaccine development.
In a press release, Regeneron CEO Leonard S Schleifer said: “Although Covid-19 has moved to an endemic stage, many people – including those with immunocompromising conditions – continue to face exposure that impacts their everyday life and could cause serious health consequences.
“American biopharmaceutical companies developed remarkable Covid-19 therapeutics and vaccines in record time, successfully changing the course of the pandemic, and we’re gratified that the US Government continues to support early research from this uniquely innovative industry.”
The current partnership expands on the previous $450m agreement between BARDA and Regeneron to supply the Covid-19 vaccineCovid-19 vaccine.
BARDA also has a collaboration agreement with Regeneron to develop a portfolio of antibodies to target ten public-risk-causing pathogens, including influenza. Recently, BARDA ordered smallpox and mpox vaccines from Bavarian Nordic as part of its preparedness response.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.